Chem. J. Chinese Universities ›› 2016, Vol. 37 ›› Issue (9): 1750.doi: 10.7503/cjcu20160088

• Polymer Chemistry • Previous Articles    

Fabrication and Characterization of Injectable Polysaccharide-polypeptide Hydrogel Based on Schiff’s Base

ZHAO Qi1,2, HE Wanying1, DUAN Lijie1,*(), ZHANG Yu2, YU Shuangjiang2, GAO Guanghui1   

  1. 1. Department of Polymer Chemistry and Physics, School of Chemical Engineering,Changchun University of Technology, Changchun 130012, China
    2. Key Laboratory of Polymer Eco-materials, Changchun Institute of Applied Chemistry,Chinese Academy of Sciences, Changchun 130022, China
  • Received:2016-02-02 Online:2016-09-10 Published:2016-08-26
  • Contact: DUAN Lijie E-mail:duanlijie@ccut.edu.cn
  • Supported by:
    † Supported by the National Natural Science Foundation of China(No.21204081)

Abstract:

The purpose of gel is applied to body with no toxic. Based on dextran, oxidized dextran(ODEX) with the different oxidation extent was prepared. At the same time, the tri-block polymers poly(lysine)-polyethylene glycol-poly(lysine)(PLL24-PEG-PLL25) was synthesized, which becomes hydrogels through the reaction between the dextran aldehyde groups and the poly-L-lysine amino groups via Schiff’s base formation. The storage modulus, degradation time of gel, and release of doxorubicin(DOX) were characterized. The results showed that gel strength increased gradually with the increasing density of aldehyde in ODEX, and the maximum storage modulus was 3100 Pa. The rheological test indicates that the storage modulus was reduced from 2160 Pa to 1730 Pa, due to the Schiff’s effect between ODEX aldehyde group and DOX amine group. The gel had a long degradation time up to 29 d. Drug release studies showed that DOX released from carrier gel was triggered by the enzyme. In Elastase solution, DOX release rate had reached up to 74.35%. The findings reveal that the hydrogel have promising applications in drug delivery in vivo.

Key words: Oxidized dextran, Polylysine, Enzyme response, Injectable polysaccharide-polypeptide hydrogel, Controlled release, Schiff’s base

TrendMD: